PARO Review (4★)

AIST / PARO Robots · Specialty

PARO

Editorial

PARO remains the clinical benchmark for non-pharmacological dementia intervention, its sensor-driven responsiveness and FDA pedigree delivering measurable reductions in agitation and caregiver burden that few competitors match. Yet the 5-hour runtime and absence of mobility cap its utility to short, supervised sessions rather than autonomous ward coverage. At $6k-plus per unit the economics favor high-volume facilities with existing reimbursement pathways, not broad adoption. Technical stasis since the 8th generation leaves it vulnerable to newer platforms offering longer endurance or multi-patient coordination. Overall it earns its niche but highlights how regulatory strength can outpace mechanical evolution in therapeutic robotics.

What this assessment is based on

Published manufacturer specifications, deployment reports, and operator accounts. ZeroGantry does not claim hands-on testing of this unit unless stated. Scores are editorial judgments from those public sources — see the methodology for how labels are assigned.

Published 2026-08-17T15:00:47.485Z

Pros

Cons

Other robot reviews

All reviews · Robot reference